Janssen

News
Sanofi partners J&J on E. coli vaccine

Sanofi partners J&J on E. coli vaccine

Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major caus

Oncology
ASCO 2023 Janssen

ASCO 2023 – Martin Vogel and Edmond Chan

In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.